24. April 2020 | 07:36 CET
BioNTech, Gilead, Memphasys - in the spotlight of investors overnight
There are topics and products that are the focus of general interest overnight. Often these are needs or problems that require a time-critical solution. The current situation surrounding the spread of the Corona Virus COVID-19 has brought numerous companies into the focus of investors in recent weeks. The backgrounds are of a very different nature. On the one hand, there are manufacturers of masks, disinfectants or respiratory equipment, as well as medical companies that may have an active ingredient for the prevention or therapy of the Corona Virus on offer. But there are also topics that are beyond the general interest and represent a huge market.
time to read:
ISIN: AU000000MEM5 , US09075V1026 , US3755581036
Growing billion dollar market
The desire of couples to have children tends to occur increasingly later in modern society. Often professional or economic reasons are in the foreground before the family picture is rounded off with their own children. However, the chances of a successful natural pregnancy decrease with increasing age. Often couples with increasing frustration then consult appropriate experts to deal with the subject of artificial insemination.
Solution increases chances of success
The Australian company Memphasys has developed a product called FELIX, which separates the high-quality sperm from the man's seminal fluid and thus increases the chances of success of artificial insemination. The advantage of FELIX is that the process only takes a few minutes and the costs of treatment can be reduced. The product is to be launched in several countries in the second half of 2020. The market for artificial insemination is growing steadily and any solution that statistically increases the chances of a successful pregnancy will be in high demand.
Memphasys shares are traded in Australia and Germany and at a price of AUD 0.048 the company has a market capitalization of AUD 36 million. Further details of the FELIX launch should increase interest in Memphasys. Introduction at the right time could be worthwhile. Further information is available in the following video interview with Executive Chairman Alison Coutts: youtu.be/kHA-UhbeZH8
Success and failure
BioNTech from Germany is currently working with Pfizer on the search for a vaccine against COVID-19. The news that tests are now being carried out on 200 people in order to obtain marketing authorisation if successful, has boosted the company's share price. The valuation of BioNTech has now risen to over EUR 10 billion. However, should the success fail to materialise, the disappointment is likely to be great.
A report on Gilead Science that the drug Remdesiver did not achieve the desired success in tests in connection with the treatment of Corona patients has caused the share price to fall and the value of the company has slid back below the USD 100 billion mark. It seems that the pandemic issue will be with us for some time to come.